BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, March 14, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2007

View Archived Issues

Medivir completes enrollment of phase III program for topical Lipsovir

Read More

bioMerieux to develop companion test for Ipsen's BN-83495

Read More

Phosphagenics submits IND for transdermal oxycodone for chronic pain

Read More

Initial phase I results show IMO-2055 plus chemotherapy feasible for solid tumors

Read More

XL-647 demonstrates antitumor activity in non-small cell lung cancer patients

Read More

Recent data on triple angiokinase inhibitor BIBF-1120 in NSCLC presented

Read More

Retreatment with Tookad phototherapy feasible and active in prostate cancer

Read More

Preclinical data on potential targets for the development of agents for sleep disorders

Read More

Cannasat Therapeutics' pain therapy delivered with IntelGenx technology in phase I trial

Read More

Asubio Pharma acquires exclusive rights to Kuvan NDA data for filing in Japan

Read More

Pharmacopeia begins phase IIa study of PS-433540 for hypertension

Read More

Patient enrollment completed for Sciele Pharma's pivotal phase III trial of glycopyrrolate

Read More

Microbia and Forest to codevelop and comarket linaclotide for gastrointestinal disorders

Read More

Vasogen to begin 300-patient confirmatory study of Celacade technology

Read More

FDA allows IND exemption for Genta's tablet formulation of G-4544

Read More

Positive tesofensine results from NeuroSearch TIPO-1 study in obesity

Read More

Polydex reports final results from phase II trial of Ushercell for BV

Read More

Schering-Plough begins two phase III studies of CCR5 antagonist vicriviroc

Read More

Xenomics and Ipsogen sign licensing agreement for diagnostic assay for AML

Read More

Idera begins dosing patients in phase I trial of IMO-2125 for HCV

Read More

Novel agents for cancer treatment covered in recent patent literature

Read More

Novel therapeutic agents for asthma disclosed in recent patents

Read More

Vion begins phase I/II brain tumor trial combining Cloretazine and Temodar

Read More

Hollis-Eden files IND for HE-3286 for inflammation

Read More

Recent patents report new therapeutic agents for disorders associated with impaired metabolism

Read More

Pegnaloxol -- a potential treatment for opioid-induced bowel dysfunction

Read More

SA-1-204 effective against extended spectrum beta-lactamases

Read More

Snapshots of clinical results in sleep research

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing